Immunoglobulin Or Antibody Binds An Expression Product Of A Cancer Related Gene Or Fragment Thereof (e.g., Oncogene, Proto-oncogene, Etc.) Patents (Class 435/330)
-
Patent number: 5906936Abstract: There are produced recombinant gene pairs which endow mononuclear cells, mainly various lymphocyte type cells, with antibody-type specificity. In specific gene pairs the rearranged gene pairs code for a binding site of an antibody molecule from the same species, of the T-cell receptor gene, or another species. Gene pairs of the invention code, for example, for antibodies specific towards tumor-specific antigens, viral antigens, modified self antigens, bacterial or fungal antigens, autoimmune type disease antigens and the like. The invention further relates to expression vectors for the effective transfection of such cell types comprising such a recombinant gene pair, to methods for producing same and to pharmaceutical compositions comprising as active ingredient an effective quantity of lymphocytes transfected with such gene pairs.Type: GrantFiled: May 4, 1993Date of Patent: May 25, 1999Assignee: Yeda Research and Development Co. Ltd.Inventors: Zelig Eshhar, Gideon Gross, Tova Waks
-
Patent number: 5889159Abstract: The invention encompasses a novel tumor marker TC1 which is present on tumor cells and absent on corresponding normal cells, nucleic acid encoding the tumor marker, and monoclonal antibodies to tumor marker TC1.Type: GrantFiled: May 28, 1996Date of Patent: March 30, 1999Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Lan Bo Chen, Shideng Bao, Yuan Liu
-
Patent number: 5885830Abstract: An anti-ribonucleotide reductase (RNR) R2 subunit monoclonal antibody KM1054, KM1056 or KM1060, which belongs to the IgG2a subclass, reacts with R2 subunit of RNR, and inhibits RNR activity, is disclosed. It is effective for immunologically detecting RNR and for immunologically detecting the presence of human cancer cells.Type: GrantFiled: February 7, 1996Date of Patent: March 23, 1999Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Toshiaki Saeki, Toshiaki Kamei, Akiko Furuya, Nobuo Hanai, Takeshi Takahashi, Masami Okabe, Motoo Yamasaki
-
Patent number: 5879898Abstract: There is marked over-expression of multiple spliced variants of the CD44 gene in tumor compared to counterpart normal tissue. This observation forms the basis of a method of diagnosing neoplasia by analysis of a sample of body tissue or body fluid or waste product. A new exon 6 of 129 bp has been located and sequenced. Antibodies specific to the exon have been prepared and are claimed as new compounds suitable for use in the detection of CD44 proteins and for the in vivo imaging and therapy of tumors.Type: GrantFiled: May 17, 1995Date of Patent: March 9, 1999Assignee: ISIS Innovation LimitedInventors: David Tarin, Yasuhiro Matsumura
-
Patent number: 5879911Abstract: A novel protein which is glycoprotein with 120,000 molecular weight and is expressed on T lymphoblastic lymphoma and leukemia cells, is useful in the diagnosis of T lymphoblastic lymphoma and leukemia.Type: GrantFiled: January 15, 1997Date of Patent: March 9, 1999Assignee: Seong Hoe ParkInventors: Seong Hoe Park, Young Mee Bae
-
Patent number: 5874255Abstract: Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM.sub.2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM.sub.2.Type: GrantFiled: May 10, 1995Date of Patent: February 23, 1999Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kazuyasu Nakamura, Masamichi Koike, Kenya Shitara, Nobuo Hanai, Yoshihisa Kuwana, Mamoru Hasegawa
-
Patent number: 5872217Abstract: A method of determining the prognosis of a solid tumor is provided, in which a sample from a patient bearing a tumor is assayed for the presence of a protein which is immunologically cross-reactive with the hpr gene product, but not with haptoglobin 1 or haptoglobin 2. Also provided is a method for preparing antibodies specific for this diagnostic marker which correlates with early relapse and metastasis of breast and other cancers. The marker can be detected using immunological methods employing antibodies specific for Hpr protein and not cross-reactive with haptoglobins 1 or 2.Type: GrantFiled: June 5, 1995Date of Patent: February 16, 1999Assignee: The Johns Hopkins UniversityInventors: Francis P. Kuhajda, Gary R. Pasternack
-
Patent number: 5858682Abstract: A monoclonal antibody which specifically binds with an E2A/pbx1 fusion epitope.Type: GrantFiled: August 2, 1996Date of Patent: January 12, 1999Assignee: PharmingenInventors: Stefan Gruenwald, Bi-Ching Sang, Craig Monell
-
Patent number: 5856182Abstract: Monoclonal antibodies have been developed which specifically bind the PSA-ACT complex without significant cross-reactivity with PSA, ACT or CG-ACT. The antibodies were generated using a unique immunogen comprising a PSA-ACT complex having bound to monoclonal antibodies against PSA and monoclonal antibodies against ACT. It is theorized that the antibodies against PSA and ACT block immunodominant sites on the PSA-ACT complex. The antibodies generated against the unique immunogen specifically bind the PSA-ACT complex, but have no significant cross-reactivity with either PSA or ACT. The monoclonal antibodies of the present invention can be used in immunoassays to specifically detect PSA-ACT in a sample.Type: GrantFiled: November 18, 1996Date of Patent: January 5, 1999Assignee: Beckman Coulter, Inc.Inventors: Kristine Kuus-Reichel, Harry Jay Linton, Janice K. Payne, Tang J. Wang
-
Patent number: 5851829Abstract: The present invention relates to a method by which one can target an undesired target molecule or target antigen, preferably a protein. The method comprises the intracellular expression of an antibody capable of binding to the target. A DNA sequence is delivered to a cell, the DNA sequence contains a sufficient number of nucleotides coding for the portion of an antibody capable of binding to the target operably linked to a promoter that will permit expression of the antibody in the cell(s) of interest. The antibody is then expressed intracellularly and binds to the target, thereby disrupting the target from its normal actions.Type: GrantFiled: March 30, 1995Date of Patent: December 22, 1998Assignee: Dana-Farber Cancer InstituteInventors: Wayne A. Marasco, William A. Haseltine
-
Patent number: 5840854Abstract: The present invention provides internalizing ligands (i.e., BR110 ligands) which specifically recognize and bind the BR110 antigen. After binding the antigen, the ligand and antigen form a complex. As a complex, the antigen can be detected using well known and developed methods and commercial systems.Type: GrantFiled: October 7, 1996Date of Patent: November 24, 1998Assignee: Bristol-Myers Squibb CompanyInventors: Karl Erik Hellstrom, Ingegerd Hellstrom, Ursula Garrigues, Stephen McAndrew, Hans Marquardt
-
Patent number: 5830470Abstract: Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM.sub.2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM.sub.2.Type: GrantFiled: September 7, 1993Date of Patent: November 3, 1998Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kazuyasu Nakamura, Masamichi Koike, Kenya Shitara, Nobuo Hanai, Yoshihisa Kuwana, Mamoru Hasegawa
-
Patent number: 5821070Abstract: This invention provides novel antibodies specifically reactive with a nuclear retinoblastoma-associated polypeptide, wherein the polypeptide specifically binds to the protein product of the retinoblastoma gene. Also provided by this invention are antibodies specifically reactive with proteins having E2F biological activity. Methods of using these antibodies also are claimed.Type: GrantFiled: October 20, 1993Date of Patent: October 13, 1998Assignee: Board of Regents of the University of Texas SystemInventors: Wen-Hwa Lee, Bei Shan
-
Patent number: 5817513Abstract: The present invention relates to immunotherapy strategies for the treatment of malignancies. The present immunotherapy strategies have gangliosides as a target. Gangliosides are glycosphingolipids which are present on normal cells and on malignant cells. On malignant cells they are more abundant and expressed in a different organization and conformation. The present invention provides antibodies which recognize these gangliosides, which antibodies are specific, have recurrent idiotypes and have value as immunoregulators. The invention further provides anti-idiotypic antibodies against anti-ganglioside antibodies. These are useful in vaccination strategies.Type: GrantFiled: December 9, 1994Date of Patent: October 6, 1998Assignee: Centro de Inmunologia MolecularInventors: Ana Maria Vazguez Lopez, Angel Mauro Alfonso Fernandez, Rolando Perez Rodriguez, Amparo E. Macias Abraham, Carlos Manuel Alvarez Valcarcel, Maria Eliana Lanio Ruiz
-
Patent number: 5811098Abstract: The molecular cloning, expression, and biological characteristics of a novel receptor tyrosine kinase related to the epidermal growth factor receptor, termed HER4/p180.sup.erbB4, are described. Antibodies to HER4 are disclosed. A HER4 ligand capable of inducing cellular differentiation of breast cancer cells is also disclosed. In view of the expression of HER4 in several human cancers and in certain tissues of neuronal and muscular origin, various diagnostic and therapeutic uses of HER4-derived and HER4-related biological compositions are provided.Type: GrantFiled: June 7, 1995Date of Patent: September 22, 1998Assignee: Bristol-Myers Squibb CompanyInventors: Gregory D. Plowman, Jean-Michel Culouscou, Mohammed Shoyab, Clay B. Siegall, Ingegerd Hellstrom, Karl E. Hellstrom
-
Patent number: 5804187Abstract: An analogue peptide that comprises the variable regions of the light or heavy chains of an antibody of a first species selectively binding to a carcinoma antigen has 1 to 46 amino acids of the framework regions per chain substituted with amino acids such as those present in equivalent positions in antibodies of a species other than the first species, or fragments thereof comprising 1 to 3 variable region CDRs per chain and optionally flanking regions thereof of 1 to 10 or more amino acids, alone or with an N-terminal fragment of 1 to 10 or more amino acids, combinations or mixtures thereof. The polypeptide may also comprise an effector agent and/or be glycosylated, and is presented as a composition with a carrier. The analogue peptides are used in diagnostic kits for carcinomas and methods for in vivo imaging and treating a primary or metastasized carcinoma, and in vitro diagnosing a carcinoma, ex vivo purging neoplastic cells from a biological fluid.Type: GrantFiled: September 30, 1993Date of Patent: September 8, 1998Assignee: Cancer Research Fund of Contra CostaInventors: Fernando J. R. do Couto, Roberto L. Ceriani, Jerry A. Peterson
-
Patent number: 5798445Abstract: Monoclonal antibodies to adenocarcinoma cells, and, in particular, breast carcinoma cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies are capable of shrinking solid tumors associated with human breast. The monoclonal antibodies identify an antigen associated with carcinomas of ductal lineage. The monoclonal antibodies, specifically, F36/22 monoclonal antibodies, can be used diagnostically and therapeutically.Type: GrantFiled: October 17, 1996Date of Patent: August 25, 1998Assignee: Health Research, Inc.Inventors: Tsann Ming Chu, Lawrence D. Papsidero
-
Patent number: 5783186Abstract: Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to "tag" Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.Type: GrantFiled: December 5, 1995Date of Patent: July 21, 1998Assignee: Amgen Inc.Inventors: Tsutomu Arakawa, Yoshiko Kita
-
Patent number: 5783404Abstract: Anti-p185.sup.HER-2/neu antibodies which are useful in the detection of HER-2/neu oncogene overexpression in biological samples are described. The antibodies are accurate and reliable in immunocytochemical or immunohistochemical assays of cell and tissue samples. Also described are methods for detecting HER-2/neu oncogene expression in a biological sample using the antibodies of the invention and a diagnostic kit comprising the antibodies. The reagents provide an accurate means of identifying certain cancer patients who have the greatest probability of relapse and/or the least likelihood of survival.Type: GrantFiled: April 13, 1995Date of Patent: July 21, 1998Assignee: Amgen Inc.Inventor: Raymond A. Koski
-
Patent number: 5780032Abstract: Provided is a method for reproducible production of cytokeratin antigen/immunogen. Cytokeratins from whole carcinoma cells are purified by preparative SDS-PAGE. Bands corresponding to cytokeratins 8, 18, and 19 are eluted from the gel, and these cytokeratins are digested to produce fragments in the size range of 10-50 Kd. The invention also relates to use of these fragments as immunogens for the production of antibodies. Furthermore, the invention relates to an immunochemical test kit to detect cancer of epithelial origin in body fluids. The kit comprises cytokeratin fragments produced by the method of the invention and antibodies to these fragments.Type: GrantFiled: June 19, 1996Date of Patent: July 14, 1998Assignee: AB IDL Immunodevelop LabInventors: .ANG.ke Silen, Bo Wiklund
-
Patent number: 5780029Abstract: The invention concerns murine antiidiotypic monoclonal antibodies which are the internal image of determinants recognized by a monoclonal antibody on high molecular weight-melanoma associated antigen (HMW-MAA), antibody derivatives, hybridoma cell lines secreting such antiidiotypic monoclonal antibodies, and processes for the preparation of such antiidiotypic monoclonal antibodies, of their derivatives and of the hybridoma cell lines. The murine antiidiotypic monoclonal antibodies are useful for the determination of antibodies directed against high molecular weight-melanoma associated antigen, for the modulation of the immune response to HMW-MAA and for the treatment of melanoma.Type: GrantFiled: October 27, 1995Date of Patent: July 14, 1998Assignee: New York Medical CollegeInventor: Soldano Ferrone
-
Patent number: 5770385Abstract: Antibodies made to a flanking region GPR(31-98) in human gastrin-releasing peptide (GRP) precursor. Since the antibodies have high affinity to GRP precursor, and the GPR precursor is highly stable in the blood, then lung cancer, especially small cell lung cancer can be diagnosed with high reliability by detecting or measuring GRP precursor in the blood of a patient using the present antibodies.Type: GrantFiled: May 17, 1996Date of Patent: June 23, 1998Assignees: Tonen Corporation, Terumo CorporationInventors: Ken Yamaguchi, Yoshio Miyake
-
Patent number: 5767246Abstract: A human monoclonal antibody specifically binding to a surface antigen of cancer cell membrane, an isolated DNA encoding the antibody, and a hybridoma producing the antibody. An anti-cancer formulation comprising the monoclonal antibody bonded to the surface of a liposome enclosing an anti-cancer agent or toxin is also provided.Type: GrantFiled: December 20, 1994Date of Patent: June 16, 1998Assignee: Mitsubishi Chemical CorporationInventors: Saiko Hosokawa, Toshiaki Tagawa, Yoko Hirakawa, Norihiko Ito, Kazuhiro Nagaike
-
Patent number: 5763274Abstract: An antibody against peanut agglutinin-(PNA)-binding glycoprotein on the surface of cells is named 103B2 and registered at the German Collection of Microorganisms and Cell Cultures GmbH, DSMZ, under the Budapest Treaty.Type: GrantFiled: August 16, 1996Date of Patent: June 9, 1998Assignee: Eberhard-Karls-Universitat TubingenInventors: Hans-Jorg Buhring, Andrew Zannettino, Paul J. Simmons
-
Patent number: 5730981Abstract: The invention relates to monoclonal antibodies of high avidity, which react specifically with the gangliosides GD3 and GQ1b, and to their use for detecting melanomas and other tumors or tissues expressing GD3 and GQ1b.Type: GrantFiled: October 20, 1994Date of Patent: March 24, 1998Assignee: Behringwerke AktiengesellschaftInventors: Klaus Bosslet, Gerhard Seemann, Wolfgang Dippold
-
Patent number: 5710255Abstract: This invention provides a family of monoclonal antibodies specific for epitopes of p110.sup.RB protein present in the nucleus. These antibodies have superior properties that prove useful for the detection of p110.sup.RB or its complexes with other cellular regulatory proteins in cells and in cell lysates. This invention also provides hybridoma cell lines that produce such monoclonal antibodies and methods of using these antibodies diagnostically, prognostically and therapeutically. Further, the invention provides a method for isolating proteins associated with p110.sup.RB proteins.Type: GrantFiled: August 15, 1994Date of Patent: January 20, 1998Assignee: Canji, Inc.Inventors: H. Michael Shepard, Shu Fen Wen
-
Patent number: 5695758Abstract: The invention relates to monoclonal antibodies against a tumor-associated antigen which is mainly derived from tumors from the group of carcinomas of the breast, ovaries and prostate, as well as adenocarcinomas of the lung, which additionally react with polymorphic epithelial mucin (PEM), to the preparation and use thereof and to the use of the epitope defined by the antibody for diagnosis and therapy.Type: GrantFiled: June 7, 1995Date of Patent: December 9, 1997Assignee: Behringwerke AktiengesellschaftInventors: Klaus Bosslet, Peter Pfleiderer, Gerhard Seemann
-
Patent number: 5688657Abstract: Monoclonal antibodies, in particular 33.28 and 31.1, and chimeric antibodies, in particular mouse/human chimeric Chi #1 specific for glycoprotein antigens of colon carcinoma-associated antigens which are immunogenic in humans, are disclosed. Such antibodies, and fragments and derivatives thereof, are useful in immunodiagnosis and immunotherapy of human colon, breast, and ovarian cancer, and for purification of antigens which can serve as immunotherapeutic agents. Methods of detecting the colon carcinoma-associated antigen in a sample, and methods for treating subjects having colon, breast, and ovarian carcinomas are disclosed.Type: GrantFiled: September 12, 1994Date of Patent: November 18, 1997Assignee: International Bio-Immune Systems, Inc.Inventors: Kwong Y. Tsang, Myron Arlen
-
Patent number: 5674994Abstract: The invention relates to polynucleotides encoding the BW 835 variable domain of an antibody against a tumor-associated antigen which is mainly derived from tumors from the group of carcinomas of the breast, ovaries and prostate, as well as adenocarcinomas of the lung, which additionally react with polymorphic epithelial mucin (PEM), and expression vectors containing the polynucleotides.Type: GrantFiled: June 6, 1995Date of Patent: October 7, 1997Assignee: Behringwerke AktiengesellschaftInventors: Klaus Bosslet, Peter Pfleiderer, Gerhard Seemann
-
Patent number: 5660994Abstract: The invention relates to the identification of insoluble cytoskeletal proteins, or fragments thereof, which are characteristic of the origin of the tissue. The invention relates as well to the method for detecting such proteins by breaking down and solubilizing the protein for immunological detection and quantitation. The method allows detection of tissue lesions or other pathological foci and metastases.Type: GrantFiled: March 1, 1995Date of Patent: August 26, 1997Assignee: Progen Biotechnik GmbHInventors: Gerda Bruder-Heid, Werner Wilhelm Franke
-
Patent number: 5658743Abstract: The invention relates to a new antigen termed BLA-36 specifically expressed on the surface of Hodgkin's cells, Reed-Sternberg cells and B lymphocytes, and to a new monoclonal antibody (anti-BLA-36) specific thereto. The antigen is characterized by the following properties:a molecular weight of about 36,000 D;the presence of an epitope recognized by antibody to said protein;specific expression by Hodgkin's cells and Reed-Sternberg cells in all subsets of Hodgkin's disease, and by activated and early proliferating B cells;no expression by T cells;capability of reacting with its antibody in both frozen and fixed/paraffin embedded tissues;a function associated with the growth of cells capable to express said antigen protein.Type: GrantFiled: April 18, 1994Date of Patent: August 19, 1997Assignee: University of Southern CaliforniaInventors: Ashraf Imam, Clive R. Taylor
-
Patent number: 5658742Abstract: This invention relates to a monoclonal antibody having affinity to human TCF-II without any affinity to HGF and determination or purification methods of TCF-II using the antibody. The monoclonal antibody can be obtained by adding a blocking solution containing a surface active agent to the culture medium containing monoclonal antibody to block antibodies other than said monoclonal antibody, followed by reaction with a solid phase antigen, TCF-II. Human TCF-II can be selectively and effectively purified or determined without any influence of the presence of HGF by using the antibody.Type: GrantFiled: March 15, 1995Date of Patent: August 19, 1997Assignee: Snow Brand Milk Products Co., Ltd.Inventors: Kanji Higashio, Nobuyuki Shima, Fumiko Oogaki
-
Patent number: 5653977Abstract: The invention provides an anti-idiotypic monoclonal antibody which elicits an immune response in a mammal against the ganglioside GD2 antigen.Type: GrantFiled: October 23, 1995Date of Patent: August 5, 1997Assignee: UAB Research FoundationInventor: Mansoor N. Saleh
-
Patent number: 5650300Abstract: The present invention provides a low cost, less toxic, anti-cancer immunotherapy which enhances the host's immune system ability to destroy or contain cancers, and also provides a diagnostic test for cancer. Specifically, the present invention provides monoclonal antibodies specific for, that is, specifically bind, oncofetal protein (OFP), a cancer cell product. Tumors treated with a single dose of the monoclonal antibodies against OFP are markedly reduced in size, and leukemic populations of cells treated with a single does of monoclonal antibodies against OFP are significantly decreased in number. Since the monoclonal antibodies of the present invention do not bind to tumor cells, the monoclonal antibody treatment overcomes the disadvantages associated with tumor cell targeting. Monoclonal antibodies to OFP offer a simple and inexpensive agent for use as a primary or adjuvant therapy against a wide variety of cancers and tumors in humans and other animals.Type: GrantFiled: May 26, 1995Date of Patent: July 22, 1997Assignee: The Ohio State UniversityInventors: Thomas E. Webb, Paul C. Stromberg, Dorothy E. Schumm
-
Patent number: 5635177Abstract: Agonist antibodies are disclosed which bind to the extracellular domain of receptor protein tyrosine kinases pTKs, and thereby cause dimerization and activation of the intracellular tyrosine kinase domain thereof. The antibodies are useful for activating their respective receptor and thereby enabling the role of the tyrosine kinase receptor in cell growth and/or differentiation to be studied. Chimeric proteins comprising the extracellular domain of the receptor pTKs and an immunoglobulin constant domain sequence are also disclosed.Type: GrantFiled: April 4, 1994Date of Patent: June 3, 1997Assignee: Genentech, Inc.Inventors: Brian D. Bennett, David Goeddel, William Matthews
-
Patent number: 5618921Abstract: A human gene has been discovered which is genetically altered in human tumor cells. The genetic alteration is gene amplification and leads to a corresponding increase in gene products. Detecting that the gene, designated hMDM2, has become amplified or detecting increased expression of gene products is diagnostic of tumorigenesis. Human MDM2 protein binds to human p53 and allows the cell to escape from p53-regulated growth. Antibodies to the human MDM2 protein and kits containing MDM2 specific antibodies are disclosed.Type: GrantFiled: February 17, 1995Date of Patent: April 8, 1997Assignee: The Johns Hopkins UniversityInventors: Marilee Burrell, David E. Hill, Kenneth W. Kinzler, Bert Vogelstein